TLR2 and neoplasm: On the basis of the encouraging efficacy and specificity shown, our study suggests that the combination of TLR2 agonists and GM-CSF is an excellent combinatorial adjuvant for triggering antitumor immunity and provides preclinical evidence of established tumor regression.